Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly*
- 22 September 1997
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacology & Therapeutics
- Vol. 62 (3) , 300-310
- https://doi.org/10.1016/s0009-9236(97)90033-3
Abstract
The multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of tolcapone, a novel catechol‐O‐methyltransferase (COMT) inhibitor, were assessed in healthy elderly volunteers receiving concomitant carbidopa and levodopa.Keywords
This publication has 16 references indexed in Scilit:
- Comparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s DiseaseEuropean Neurology, 1997
- Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa.British Journal of Clinical Pharmacology, 1995
- Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in ratsEuropean Journal of Pharmacology, 1995
- Clinical Potential of Catechol-O-Methyltransferase (COMT) Inhibitors as Adjuvants in Parkinsonʼs DiseaseCNS Drugs, 1994
- Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in ratsEuropean Journal of Pharmacology, 1993
- Treatment of Parkinson's DiseaseNew England Journal of Medicine, 1993
- Different in vivo properties of three new inhibitors of catechol O‐methyltransferase in the ratBritish Journal of Pharmacology, 1992
- Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1990
- Book reviewsZeitschrift für Neurologie, 1990
- New selective COMT inhibitors: useful adjuncts for Parkinson's disease?Trends in Pharmacological Sciences, 1989